Asthma Exacerbations are Associated with a decline in Lung Function : A Longitudinal Population-Based Study

Funding This study was conducted by the Observational and Pragmatic Research Institute (OPRI) Pte Ltd and was partially funded by Optimum Patient Care Global and AstraZeneca Ltd. No funding was received by the Observational & Pragmatic Research Institute Pte Ltd (OPRI) for its contribution. Acknowledgements The authors thank the UK primary care sites that contributed anonymised patient data to this study; Drs Jaco Voorham and Marjan Kerkhof for their contributions to the preparation and analysis of the data; and Audrey Ang and Andrea Teh Xin Yi for coordinating logistical and administrative support for the development of this manuscript. We also thank our Thorax peer reviewers for their in-depth comments and suggestions which greatly improved the quality of this article.Peer reviewedPostprin

Asthma phenotyping in primary care : applying the International Severe Asthma Registry eosinophil phenotype algorithm across all asthma severities.

Funding: The OPCRD is established and maintained by Optimum Patient Care (OPC) Ltd. This study was funded by AstraZeneca and conducted collaboratively with the OPRI Pte Ltd and OPC Global Ltd. Acknowledgements We thank James Zangrilli, MD, and the entire ISAR Steering Committee for their valued contribution to the design of the study and interpretation of findingsPeer reviewedPublisher PD

Potential severe asthma hidden in UK primary care

Funding: ISAR is conducted by Observational & Pragmatic Research Institution (OPRI), and co-funded by OPC Global and AstraZeneca. This research study was co-funded by AstraZeneca and Optimum Patient Care Global Limited, including access to the Optimum Patient Care Research Database (OPCRD).Peer reviewedPublisher PD

Effectiveness of initiating biologics in severe asthma patients with high steroid exposure

Peer reviewedPostprin

Russian Point of View on German Rossievedenie

This review deals with the chapter about modern Russian Studies in Germany in the collective monograph “Izuchenie Rossii sovremennymi istorikami Zapada i Vostoka”, recently published under the editorship of N. V. Trubnikova. Its authors, the Tomsk historians V. V. Ageeva and M. A. Shtanko, have set a promising goal for their research: to approach the German rossievedenie in their overview covering the period from 1975 until 2014 with theoretical-methodological criteria instead of the more common in such cases political ones. In order to realize this project, they proposed to divide modern German historiography into three periods, with the latter one which covers the years 2005–2014 being a no less important innovation. However, it fell short of the reader’s expectations. Unfortunately, the chapter “Sovremennoe nemetskoe rossievedenie: spetsifika diskursa, tematicheskie polia i protsess institucionalizacii” is a mere compilation of superficially adapted facts, conclusions and ideas mostly taken from other works. V. V. Ageeva and M. A. Shtanko do not seem to have paid attention to the fact that some of the data they draw on have already lost its actuality. Statistical material serves largely to confirm their own postulates, and most references to German historians and their studies are inaccurate and misspelled, which does not enhance comprehension. Overall, the reader gets the impression that the authors were due to finish their work under some time pressure. This probably would explain why they chose “to take the easy way out” — in the end, the welcoming innovative theses expressed at the beginning of the chapter are abandoned, whereas outdated clichés — confirmed.This article was prepared within the framework of the state project of the Ministry of Science and Higher Education of the Russian Federation “Regional Identity of Russia: Comparative Historical and Philological Studies” (Laboratory for the Study of Primary Sources, Ural Federal University) No. FEUZ- 2020-0056

Demographic and Clinical Characteristics of Patients with Severe Asthma in the Asian Pacific Region : data from the International Severe Asthma Registry (ISAR)

Peer reviewe

Association between T2-related co-morbidities and effectiveness of biologics in severe asthma

Acknowledgments The authors thank Mr. Joash Tan (BSc, Hons), of the Observational and Pragmatic Research Institute (OPRI), and Ms Andrea Lim (BSc, Hons) of the Observational Pragmatic Research Institute (OPRI) for their editorial and formatting assistance that supported the development of this publication. Funding statement: This study was conducted by the Observational and Pragmatic Research Institute (OPRI) Pte Ltd and was partially funded by Optimum Patient Care Global and AstraZeneca Ltd. AstraZeneca UK LimitedPeer reviewe

Development of the International Severe Asthma Registry (ISAR) : A Modified Delphi Study

This study is cofunded by Optimum Patient Care Global and AstraZeneca.Peer reviewedPostprin

Global variability in administrative approval prescription criteria for biologic therapy in severe asthma

Background Regulatory bodies have approved five biologics for severe asthma. However, regional differences in accessibility may limit the global potential for personalized medicine. Objective To compare global differences in ease of access to biologics. Methods In April 2021, national prescription criteria for omalizumab, mepolizumab, reslizumab, benralizumab, and dupilumab were reviewed by severe asthma experts collaborating in the International Severe Asthma Registry. Outcomes (per country, per biologic) were (1) country-specific prescription criteria and (2) development of the Biologic Accessibility Score (BACS). The BACS composite score incorporates 10 prescription criteria, each with a maximum score of 10 points. Referenced to European Medicines Agency marketing authorization specifications, a higher score reflects easier access. Results Biologic prescription criteria differed substantially across 28 countries from five continents. Blood eosinophil count thresholds (usually ≥300 cells/μL) and exacerbations were key requirements for anti-IgE/anti–IL-5/5R prescriptions in around 80% of licensed countries. Most countries (40% for dupilumab to 54% for mepolizumab) require two or more moderate or severe exacerbations, whereas numbers ranged from none to four. Moreover, 0% (for reslizumab) to 21% (for omalizumab) of countries required long-term oral corticosteroid use. The BACS highlighted marked between-country differences in ease of access. For omalizumab, mepolizumab, benralizumab, and dupilumab, only two, one, four, and seven countries, respectively, scored equal or higher than the European Medicines Agency reference BACS. For reslizumab, all countries scored lower. Conclusions Although some differences were expected in country-specific biologic prescription criteria and ease of access, the substantial differences found in the current study present a challenge to implementing precision medicine across the world

ISAR Delphi Process Variables Workbook

This workbook contains the lists of variables that were involved in the ISAR Modified Delphi Process.Sheet 1: Matched "Potential Core" Variables(List of Matching variables from the BTS and SAWD registries)Sheet 2: Unmatched "Suggested" Variables(List of Non-matching variables from the BTS and SAWD registries)Sheet 3: Variables removed(List of variables removed from the total number of matching and non-matching variables